
    
      The study consisted of two periods:

        -  a double blind treatment period of 12 weeks followed by,

        -  an open label clopidogrel treatment period in a subset of patients.

      All patients should receive aspirin (81-100 mg once daily) as a background therapy during
      investigational product administration.
    
  